Company intelligence / Profile preview
Taivex Therapeutics
Taipei City, Taipei, Taiwantaivex.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
T‑1101 completed Phase I with encouraging safety and preliminary efficacy in neuroendocrine tumors; recommended Phase II dose established. T‑1201 nearing end of Phase I with promising safety/efficacy in melanoma/cholangiocarcinoma. T‑1301 is in ongoing Phase I for GIST/AML. T‑1501 is preclinical, expected to enter clinic in late 2025.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesSmall molecule-drug conjugatesMulti-target tyrosine kinase inhibitors
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
National Health Research Institutes Taiwan—technology transfer and co-development on multiple assetsDevelopment Center for Biotechnology—co-development on early programs
Beyond the preview
Go deeper on Taivex Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Taivex Therapeutics.